Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome.

PURPOSE Expression of the genes ERG (v-ets erythroblastosis virus E26 oncogene homolog) and BAALC (brain and acute leukemia, cytoplasmic) shows similarity during hematopoietic maturation and predicts outcome in acute myeloid leukemia. We hypothesized that like ERG, BAALC expression might be of prognostic significance in acute T-lymphoblastic leukemia (T-ALL) and that ERG and BAALC expression together would better identify the patient's risk profile. PATIENTS AND METHODS ERG and BAALC mRNA expression were determined by real-time reverse transcriptase polymerase chain reaction in 153 adults with T-ALL. Patients were designated low or high ERG expressers and low or high BAALC expressers. RESULTS High BAALC expression correlated with a higher frequency of early T-ALL (P < .0001), CD34 positivity (P < .0001), coexpression of myeloid markers (P = .0001), and high ERG expression (P = .03). High BAALC compared with low BAALC patients had an inferior relapse-free survival (RFS; P = .0008) and overall survival (OS; P = .0001). In contrast, patients with low expression of both ERG and BAALC (representing 41% of all T-ALL patients) had the most favorable outcome (P < .0001; 4-year RFS: low ERG/low BAALC 81%; P < .0001; 4-year OS: low ERG/low BAALC 69%). On multivariable analysis, low ERG/low BAALC expression was of independent favorable prognostic significance (RFS, P = .001; OS, P = .003). CONCLUSION Low expression of both ERG and BAALC identifies T-ALL patients with a distinctly favorable long-term outcome.

[1]  T. Naoe,et al.  Clinical features and outcome of T-lineage acute lymphoblastic leukemia in adults: a low initial white blood cell count, as well as a high count predict decreased survival rates. , 2007, Leukemia research.

[2]  Dejan Juric,et al.  Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Blann,et al.  Detection of circulating endothelial cells: CD146-based magnetic separation enrichment or flow cytometric assay? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Bloomfield,et al.  High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T. Naoe,et al.  Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. , 2006 .

[6]  C. Bloomfield,et al.  BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  E. Thiel,et al.  Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. , 2006, Blood.

[8]  Bob Löwenberg,et al.  On the road to new drugs in acute myeloid leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Foà,et al.  Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. , 2006, Blood.

[10]  M. Caligiuri,et al.  Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Bloomfield,et al.  Co-Expression of BAALC with ERG, TCF4, and CD133 Indicates a Shared Pathway in Acute Myeloid and Lymphoblastic Leukemia. , 2005 .

[12]  J. Downing,et al.  Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Armstrong,et al.  Molecular genetics of acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. Dombret,et al.  Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Sandya Liyanarachchi,et al.  Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Caligiuri,et al.  BAALC, a novel marker of human hematopoietic progenitor cells. , 2003, Experimental hematology.

[17]  M. Caligiuri,et al.  BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. , 2003, Blood.

[18]  E. Thiel,et al.  Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10−/CD24−/CD65s+/CD15+ B-cell phenotype , 2003, Leukemia.

[19]  C. Sebban,et al.  Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period , 2001, Leukemia.

[20]  M. Caligiuri,et al.  BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Ioanna G Maroulakou,et al.  Expression and function of Ets transcription factors in mammalian development: a regulatory network , 2000, Oncogene.

[22]  E. Rothenberg,et al.  Precise developmental regulation of Ets family transcription factors during specification and commitment to the T cell lineage. , 1999, Development.

[23]  D. Hoelzer,et al.  Treatment of adult acute lymphoblastic leukemia. , 1999, Hematology. American Society of Hematology. Education Program.

[24]  Y. Hayashi,et al.  Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16;21)(p11;q22) and identification of a novel transcript. , 1997, Blood.

[25]  A Orfao,et al.  Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). , 1995, Leukemia.

[26]  J. Downing,et al.  Tumor-specific genetic lesions and their influence on therapy in pediatric acute lymphoblastic leukemia. , 2006, Hematology. American Society of Hematology. Education Program.

[27]  C. Bloomfield,et al.  Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. , 2006, Hematology. American Society of Hematology. Education Program.

[28]  W. Hiddemann,et al.  A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group. , 2004, Haematologica.